Last reviewed · How we verify
Relapsing acute myeloid leukemia with a susceptible IDH1 mutation
Approved treatments
- Rezlidhia · Rigel Pharms
Olutasidenib inhibits mutated IDH1, reducing 2-HG levels in AML cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Relapsing acute myeloid leukemia with a susceptible IDH1 mutation patent landscape — cliff calendar, originator estates, attackable patents
- Relapsing acute myeloid leukemia with a susceptible IDH1 mutation treatment landscape brief
- Relapsing acute myeloid leukemia with a susceptible IDH1 mutation treatment updates RSS
Frequently asked questions about Relapsing acute myeloid leukemia with a susceptible IDH1 mutation
What drugs treat Relapsing acute myeloid leukemia with a susceptible IDH1 mutation?
Tracked treatments include Rezlidhia.
What is the treatment for Relapsing acute myeloid leukemia with a susceptible IDH1 mutation?
Standard treatment for Relapsing acute myeloid leukemia with a susceptible IDH1 mutation includes Rezlidhia. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Relapsing acute myeloid leukemia with a susceptible IDH1 mutation patent cliff · Relapsing acute myeloid leukemia with a susceptible IDH1 mutation CI report
- Treatment: Rezlidhia · Rigel Pharms
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing